Tracking a Cushing's syndrome drug in Real-World patients for 3 years
NCT ID NCT05382156
Summary
This study is observing patients with Cushing's syndrome who are already taking the medication osilodrostat in their regular care. Researchers will follow about 200 patients for up to 3 years to collect information on the drug's long-term safety and how well it works to control the disease. The goal is to better understand the real-world benefits and risks of this treatment over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOGENOUS CUSHING'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amedes Experts
Hamburg, 20095, Germany
-
Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza
Roma, 00189, Italy
-
Azienda Ospedaliera Universitaria "Federico II"
Naples, 80131, Italy
-
Azienda Ospedaliero Universitaria Ospedali Riuniti
Ancona, 60126, Italy
-
Barrow Neurological Institute
Phoenix, Arizona, 85013, United States
-
CHU de Grenoble site Nord
Grenoble, 38043, France
-
CHU de Nantes-Hopital Laennec
Nantes, 44800, France
-
Charité Universitaetsmedizin Berlin
Berlin, 10117, Germany
-
Emory University School
Atlanta, Georgia, 30322, United States
-
Endocrinology Research Associates, Inc.
Columbus, Ohio, 43201, United States
-
Endokrinologikum Frankfurt
Frankfurt, 60596, Germany
-
Erasmus MC
Rotterdam, 3015 GD, Netherlands
-
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
-
Groupement Hospitalier Sud - Hôpital Bicêtre
Le Kremlin-Bicêtre, 94275, France
-
Hopital Claude Huriez - CHRU Lille
Lille, 59037, France
-
Hopital Larrey
Toulouse, 31000, France
-
Hopital de la Conception - APHM
Marseille, 13005, France
-
Hospices Civiles de Lyon
Bron, 69677, France
-
Hôpital Cochin
Paris, 75679, France
-
Hôpital Haut-Lévêque
Bordeaux, 33604, France
-
Hôpital de Brabois
Nancy, 54500, France
-
Indiana University Schl-med
Indianapolis, Indiana, 46202, United States
-
Ludwig-Maximilians University of Munich
Munich, Germany
-
Massachusetts General Hospital
Boston, Massachusetts, 02114-2696, United States
-
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
-
Medicover Berlin-Mitte MVZ
Berlin, 10117, Germany
-
Medicover Köln
Cologne, 50939, Germany
-
Medicover MVZ Oldenburg
Oldenburg, 26122, Germany
-
Medicover Neuroendokrinologie
Munich, 81667, Germany
-
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, 10021, United States
-
NYU Grossman School of Medicine
New York, New York, 10017, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Oregon Health And Science University
Portland, Oregon, 97239, United States
-
Policlinico Umberto I
Roma, 00186, Italy
-
Radboud University Nijmegen
Nijmegen, 6500, Netherlands
-
St Elizabeth Physicians
Covington, Kentucky, 41011, United States
-
Universitaet Bielefeld - Klinikum Bielefeld - Mitte
Düsseldorf, Germany
-
Universitaetsklinikum Frankfurt Goethe-Universitaet
Frankfurt, 60590, Germany
-
Universitaetsklinikum Wuerzburg
Würzburg, 97080, Germany
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, 19104, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.